Mayo to use AI-powered digital pathology to support drug development

Rochester, Minn.-based Mayo Clinic BioPharma Diagnostics has partnered with artificial intelligence-powered spatial biology company Nucleai to support drug development using AI.

Advertisement

Under the partnership, Mayo Clinic’s multimodal datasets, laboratories and clinical expertise will combine with Nucleai’s AI platform to develop new offerings for biomarker discovery and validation, end-to-end spatial biology testing and algorithm deployment for clinical trials and diagnostic use, according to a June 4 press release from Nucleai. 

The aim is for both entities to create new digital pathology solutions, technologies and services to support drug development and clinical practice.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.